Meet the innovators defining the future of healthcare and technology.

Life Sciences
Stage: All
Status: All
Theme: All
Company
First invested
Current status
Description
Early
Private
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.
Public/PIPES
IPO/Acquired
NASDAQ: AVEO
Acquired by LG Chem
Commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
Early
Private
Abcuro is a clinical-stage company developing Ulviprubart, a FIC anti-KLRG1 antibody in Ph2/3 pivotal trials for Inclusion Body Myositis (IBM).
Public/PIPES
IPO/Public
NASDAQ: ACAD
Biopharmaceutical company focused on innovative small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders
Seed
Acquired
Acquired by Johnson & Johnson
Developer of Balloon Sinuplasty
Early
Acquired
Acquired by Nicox S.A.
Specialty pharmaceutical company focused on the development of therapeutics to treat front of the eye diseases
Seed
IPO/Public
NASDAQ: ACRV
Acrivon is developing best-in-class targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon’s unprecedented patient selection method represents a paradigm change in precision oncology drug development.
Early
IPO/Public
NASDAQ: ADAP
Biopharma company developing affinity enhanced T cell receptor (TCR) engineered T cells to treat hematologic and solid tumor cancers.
Public/PIPES
IPO/Public
NASDAQ/SIX: ADXN
Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders.
Early
Acquired
Acquired by Eli Lilly & Company
China-based, fabless semiconductor company
Early
IPO/Public
German-domiciled and NASDAQ-traded company developing a variety of immuno-oncology therapeutics.
Early
Private
An innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases.
Seed
Private
Ajax is a biotechnology company that focuses on cardiovascular devices
Public/PIPES
IPO/Public
NASDAQ: AKTX
Biotechnology company developing advanced therapies for autoimmune and inflammatory diseases.
Early
IPO/Acquired
NASDAQ: AKUS
Acquired by Eli Lilly and Company
Akouos is a biotechnology company focused on restoring and preserving hearing.
Public/PIPES
IPO/Public
NASDAQ: ALXA
Staccato
Public/PIPES
IPO/Public
NASDAQ: ALIM
Biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals
Growth
Acquired
Acquired by Concentra Biosciences
Biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.
Early
Private
Ultra-sustained analgesic products for post-surgical pain management.
Early
Private
Adaptive, closed-loop neuromodulation device targeting the pudendal nerve to treat mixed urinary incontinence.
Public/PIPES
IPO/Public
NASDAQ: FOLD
Oral pharmacological chaperone protein therapies to address diseases that result from protein misfolding
Early
Acquired
Acquired by Pfizer
Developing a novel class of drugs to treat life‐threatening systemic fungal infections.
Early
Acquired
Acquired by Medtronic
Products for the endovascular surgery market
Early
IPO/Public
NASDAQ: ANNX
Annexon Biosciences is leading the development of therapeutic products that halt the progression of complement-mediated neurodegeneration. Annexon’s antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in the loss of nerve connections and inflammation.
Early
Acquired
Acquired by Microvena
Novel device and procedure for preventing cardioembolic stroke in patients with Atrial Fibrillation
Early
IPO/Acquired
NASDAQ: ACLX
Acquired by: GILEAD
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
Early
IPO/Public
NASDAQ: ARDX
Focused on the discovery and development of novel therapeutics acting exclusively in the gastrointestinal tract and devoid of systemic exposure
Early
IPO/Acquired
NASDAQ: ASPM
Acquired by Covidien
Noninvasive anesthesia monitoring systems
Public/PIPES
IPO/Public
NASDAQ: AUPH
Clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need.
Growth
Private
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation of small-molecule and ADC oncology therapies for patients.
Early
Private
AviadoBio is a biotechnology company developing transformative gene therapies for neurodegenerative disorders using a novel neuroanatomy-led approach to drug delivery.
Seed
Private
Basalt is a tool that integrates into EMRs to help clinical and admissions teams make faster, more consistent decisions by pulling together patient data, applying clinical criteria, and surfacing what actually matters without manual chart digging.
Early
Acquired
Acquired by Life Technologies
Distributor of enzymes and other products allowing manipulation of DNA
Early
IPO/Public
NASDAQ: BDTX
Black Diamond discovers and develops next-wave precision cancer medicines to treat patients with genetically defined cancers driven by oncogenes activated by allosteric mutations.
Early
Private
Brenig is a small molecule drug development company that utilizes an AI/ML approach via a partnership with Expert Systems Inc., a drug accelerator that has spawned multiple best-in-class clinical candidates across multiple therapeutic areas.
Early
Acquired
Acquired by Boston Scientific
Medical device company pioneering solutions to recanalize chronic total occlusions
Growth
IPO/Public
NASDAQ: CRSP
A Basel, Switzerland and Boston, MA-based biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines with the potential to cure serious human genetic diseases
Public/PIPES
IPO/Acquired
NYSE: CTIC
Acquired by Sobi
CTI BioPharma develops drugs that leverage the its expertise in blood-related cancers to address unmet medical needs and find therapies that are less toxic.
Early
Acquired
Acquired by Covidien
Developing a paclitaxel-coated drug-eluting balloon (DEB) for use in treating peripheral vascular disease
Early
IPO/Public
NASDAQ: CVRX
Rheos™ Baroreflex Hypertension Therapy System for treatment of refractory hypertension
Public/PIPES
IPO/Acquired
NASDAQ: CADX
Acquired by Mallinckrodt
Hospital-focused biopharmaceutical company
Early
IPO/Acquired
NASDAQ: CTSI
Guidant; Boston Scientific
Instruments and procedures to advance coronary artery bypass graft surgery
Early
Private
Medical device company that is developing a catheter-based neuromodulation solution for the treatment of acute decompensated heart failure (ADHF).
Early
IPO/Acquired
NASDAQ: CVIS
Boston Scientific
Ultrasonic imaging catheter and instrument system for diagnosis of coronary, peripheral and carotid arteries
Seed
Acquired
Acquired by Bristol Myers Squibb
Discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease
Early
Private
Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases.
Early
Acquired
Acquired by Cartiva; Wright Medical Group
Medical device company developing innovative solutions for patients with osteoarthritis and cartilage damage
Early
Acquired
Acquired by Wright Medical
Developer of innovative products for the treatment of cartilage injuries and osteoarthritis
Public/PIPES
IPO/Acquired
NASDAQ: CASC
Acquired by Seattle Genetics
Clinical-stage biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer.
Growth
IPO/Public
NASDAQ: CBIO
Biopharmaceutical company focused on drugs to treat CNS disorders by targeting neuronal nicotinic receptors
Public/PIPES
IPO/Public
NASDAQ: CELC
Minneapolis-based clinical stage biotechnology company focused on the development of molecularly targeted drugs for cancer.
Early
Private
Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development.
Early
IPO/Public
NASDAQ: CERCU
Clinical stage biopharmaceutical company focused on the development of drugs to treat diseases of the central nervous system
Public/PIPES
IPO/Public
NASDAQ: CSBR
Global preclinical research and clinical specialty testing provider driving excellence in oncology drug development programs.
Early
Acquired
Acquired by Shanghai Pharmaceuticals
Provider of pharmaceuticals, medical supplies and health care information technologies to China's fast-growing healthcare services industry
Early
Private
ChromaCode uses patented mathematical methods and algorithms to enrich signal processing from the most popular life science instrumentation. Their initial products enable high multiplexing of biological tests using existing real-time PCR instruments at a very low cost.
Early
Private
Discovering and developing novel small molecule therapies for difficult-to-treat cancers
Early
IPO/Acquired
NASDAQ: CMTA
Acquired by Ipsen
Biopharmaceutical company focused on developing treatments for rare diseases
Early
IPO/Public
NASDAQ: CLVS
Focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets
Early
Private
A next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases.
Growth
Acquired
Acquired by Teva Pharmaceuticals
Focused on development of biotherapeutics for treatment of cancer, heart disease
Early
Private
Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to make every pregnancy around the world safer.
Early
Private
Developing disease-modifying nitro fatty acid platform technology for patients with fibrosis and inflammation-associated orphan diseases.
Early
IPO/Public
NASDAQ: CPTS
Products for the reproductive health market
Seed
Private
CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world.
Early
Acquired
Acquired by Horizon Therapeutics
Treatment of Systemic Sclerosis.
Early
Private
DOTS (Detection On The Spot) is a health tech company creating a revolutionary diagnostics platform with consumer and industrial applications that is changing the field of point of care detection.
Early
IPO/Acquired
NASDAQ: DERM
Acquired by Lilly
A company focused on developing and commercializing innovative new therapies in dermatology
Early
Acquired
Acquired by Schering AG
Therapeutic peptides and imaging agents for thrombus, atherosclerosis and inflammation
Early
IPO/Public
Synthetic peptides for treatment of allergies and asthma
Growth
Acquired
Protein Design Labs
Pharmaceutical company focused on the quality of therapeutics in the acute-care hospital setting
Seed
Private
Biotech company aimed at creating the next generation of genetic medicines.
Early
IPO/Public
St. Jude Medical
Tools for diagnosing and treating cardiac arrhythmias.
Early
Acquired
Acquired by Boston Scientific
NexStent for next-generation carotid artery stenting
Early
Acquired
Acquired by Aerie Pharmaceuticals
Biotechnology startup focused on developing ophthamology products
Early
Acquired
Acquired by Alkermes
Polymer based drug delivery systems for therapeutic proteins
Early
Acquired
Acquired by Ajax Health LLC
EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics, Inc.) is a medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB.
Early
IPO/Acquired
NASDAQ: EPZM
Acquired by Ipsen
Biopharmaceutical company that is creating innovative drugs for major diseases based on important discoveries emerging from the field of Epigenetics
Public/PIPES
IPO/Public
NASDAQ: ERYP
A clinical-stage biopharma company based in Lyon, France
Early
Acquired
Acquired by Incyte
Escient is a clinical-stage pharmaceutical company focused on discovering and developing first-in-class therapies to address serious, unserved medical needs. The company is led by an experienced team with specific expertise in GPCR drug discovery and development. Escient's pipeline consists of two novel antagonists targeting MRGPRX4 for the treatment of cholestatic pruritis and MRGPRX2 for mast cell mediated disorders.
Growth
Acquired
Acquired by Allergen
Specialty pharmaceutical company focused on urological and women's health products
Seed
Acquired
Acquired by Abbott
Developer of MitraClip for catheter-based edge-to-edge mitral valve repai
Early
Private
Premier medical device incubator focused on developing patient-driven solutions to persistent medical problems.
Early
Private
Implantable remote monitoring device for heart failure patients.
Early
Private
The Foundry is the premier medical device company incubator for inventors to rapidly transform their concepts into companies.
Early
IPO/Acquired
NASDAQ:FOXH
Acquired by Coviden
Medical devices for the treatment of coronary and peripheral arterial disease
Early
Private
Developing a portfolio of clinical-stage small molecule superoxide dismutase mimetics for the treatment of mucositis, cancer and fibrosis
Early
IPO/Public
Genzyme
Non-absorbed, polymer-based pharmaceuticals for the selective gastro-intestinal elimination of substances
Early
IPO/Acquired
Acquired by Sandoz Pharmaceuticals
Products and services based on proprietary technology to implement human gene therapy
Growth
IPO/Public
NASDAQ: GERN
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Early
IPO/Public
NASDAQ: GLYC
Small molecule therapeutics that mimic the action of carbohydrates to treat inflammatory and infectious diseases
Public/PIPES
IPO/Public
NSDAQ: GOSS
Biopharmaceutical company developing seralutinib for the treatment of pulmonary arterial hypertension (PAH).
Early
IPO/Public
Johnson & Johnson
Endometrial ablation system for the treatment of excessive uterine bleeding
Public/PIPES
Acquired
Acquired by Inverness Medical
INRatio anti-coagulation monitor for patient self-testing
Early
Acquired
Acquired by Eli Lilly and Company
Private biopharmaceuticals company pioneering the discovery of novel drugs using its expertise in Transient Receptor Protocols in ion channels and molecular regeneration
Early
IPO/Acquired
NASDAQ: HPTX
Acquired by Horizon Pharma
Specialty therapeutics company focused on gastrointestinal and hepatology diseases and programs
Early
IPO/Public
NASDAQ: IMRA
Developing IMR-687, an IND-ready PDE9 (phosphodiesterase 9) inhibitor for sickle cell disease
Public/PIPES
IPO/Public
Amgen
Lymphokines for therapeutic use as anti-cancer agents supporting the human immune system
Public/PIPES
IPO/Acquired
NASDAQ: IMMU
Acquired by Gilead Sciences (NASDAQ: GILD)
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer.
Public/PIPES
IPO/Public
NASDAQ: INFI
Clinical-stage biotechnology company developing a therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer.
Public/PIPES
IPO/Acquired
Acquired by Bristol Myers Squibb
Biopharmaceutical company focused on novel antibody-based products for serious hospital-associated bacterial and fungal infections
Early
Acquired
Acquired by BioMarin Pharmaceutical
Biotechnology company developing new medicines to treat rare disorders of calcification with initial focus on enzyme replacement therapy for devastating and debilitating rare diseases that largely impact infants, children and young adults.
Early
IPO/Acquired
NYSE:PHG
Acquired by Royal Philips
A medical device company that is developing a novel, minimally invasive medical device for the treatment of peripheral arterial disease (PAD).
Public/PIPES
IPO/Acquired
NASDAQ: ITMN
Acquired by Roche Holding AG
Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.
Early
Private
Developing device-based therapies for soft-tissue injuries of the spine
Public/PIPES
IPO/Public
NASDAQ: IVA
Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
Early
Acquired
Acquired by Novo Nordisk
Inversago Pharma specializes in the development of new therapies focusing on CB1blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
Early
IPO/Acquired
Acquired by Intercell AG
Vaccines and immune system stimulants delivered through novel needle-free transcutaneous immunization
Early
IPO/Public
Cutera
Ophthalmic probes and diode laser-based systems
Early
Acquired
Acquired by Alcon
Developing products for the treatment of eye diseases
Early
IPO/Acquired
NASAQ: KRRO
Merged with Frequency Therapeutics
A preclinical-stage biopharma company that is developing novel RNA editing therapeutics to treat genetically-driven disease. Korro’s OPERA platform coopts the body’s ADAR system to make targeted edits to a single RNA base.
Early
Private
Collaborates with client hospitals and community physicians in the development and management of a proven disease management program for the care of gastroesophageal reflux disease (GERD)
Public/PIPES
Private
LeonaBio is dedicated to the development of novel therapeutics for diseases with high unmet needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patient’s lives.
Public/PIPES
IPO/Public
NASDAQ: LXRX
Biopharmaceutical company that has harnessed the power of genetics for drug discovery.
Early
IPO/Public
Invitrogen
Tissue culture media, immunodiagnostics and test kits for the life sciences research field
Early
IPO/Public
NASDAQ: LQDA
Utilizes a proprietary nanotechnology platform to develop precisely engineered products in the materials and life sciences sectors
Early
IPO/Acquired
NASDAQ: LOXO
Acquired by Eli Lilly & Co.
Biopharma company developing targeted cancer therapies for genetically-defined patient populations
Early
Acquired
Acquired by Shire
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health.
Early
Acquired
Acquired by NewLink Genetics
Developing a novel therapeutic for the rare disease Creatine Transporter Deficiency, an inborn error of metabolism
Growth
Private
Lungpacer Medical Inc. is developing a novel therapeutic solution for preserving or restoring the integrity and strength of the diaphragm muscle in critically ill patients who require mechanical ventilation.
Early
IPO/Public
NASDAQ: MBX
Advancing potential breakthrough medicines for rare endocrine diseases of substantial medical need with validated molecular targets.
Public/PIPES
IPO/Public
NASDAQ: MEIP
Oncology company focused on the clinical development of novel therapies for cancer
Early
Private
Next-generation percutaneous left ventricular assist device targeting high-risk percutaneous coronary intervention and cardiogenic shock.
Early
IPO/Public
NASDAQ: MRKR
Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood and solid tumor cancers.
Early
IPO/Public
NASDAQ: MRSN
Biopharmaceutical company that is creating the next generation of antibody drug conjugates using its Fleximer-ADC technology
Early
IPO/Public
Metacrine is a biotech company developing innovative therapeutics for liver, gastrointestinal, and metabolic diseases. The lead program is a best-in-class FXR agonist for multiple diseases, including non-alcoholic steatohepatitis (NASH).
Early
IPO/Public
NASDAQ: UTRS
Medical device start-up company focused on women's health care
Early
IPO/Public
NASDAQ: MIRN
Biopharmaceutical company focused on microRNA (miRNA)-directed oncology therapies
Early
IPO/Public
NASDAQ: MIRM
Mirum Pharmaceuticals, Inc. is a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.
Growth
IPO/Public
NASDAQ: GLUE
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins by creating a platform that designs small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable.
Early
Acquired
Acquired by Allergan
Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases.
Early
Private
Implantable shock absorber (ISA) that unloads the knee, relieves pain, and improves function for patients with osteoarthritis.
Early
IPO/Public
IPO/Public Gilead Sciences
Biopharmaceutical company focused on small molecule therapeutics for the treatment of cardiovascular disorders.
Public/PIPES
IPO/Public
NASDAQ: NKTR
Research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet needs.
Public/PIPES
IPO/Public
Covidien
Patient monitoring instruments and disposable supplies for use in surgery
Early
Acquired
Teleflex
Developer of the UroLift
Early
Private
Developing a personal use device to treat migraine using transcranial magnetic stimulation
Early
IPO/Public
NASDAQ: NPCE
Developing implantable devices for the treatment of neurological disorders by responsive brain stimulation
Early
IPO/Acquired
NYSE: NVRO
Next generation high frequency spinal cord stimulation for the treatment of chronic pain
Growth
Private
Leading Chinese producer of active pharmaceutical ingredients (API) for global markets
Early
Private
Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
Early
IPO/Acquired
NASDAQ: NITE
Acquired by Biogen
Private biopharmaceutical company focused on the development of therapies for retinal dystrophies.
Early
IPO/Public
NASDAQ: NKTX
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer.
Growth
Acquired
Cytyc Corporation
Cytyc
Innovative medical devices to improve the quality and cost-effectiveness of healthcare for women
Early
Private
China's leading speciality pharmaceutical developer
Early
Acquired
Aytu BioScience, Inc.
Nuelle™ is a sexual wellness company focused on delivering groundbreaking solutions made specifically for women, backed by science that promote individual vitality and healthy relationships.
Early
IPO/Public
NASDAQ: OBSV
ObsEva is a clinical stage biopharmaceutical company focusing on the development of a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth.
Early
Acquired
Acquired by Allergan
Developing a novel treatment for Dry Eye, a disease affecting millions of people worldwide
Early
IPO/Acquired
NASDAQ: OMTH
Acquired by Astrazeneca
Emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia
Early
Private
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery.
Public/PIPES
IPO/Acquired
NASDAQ: OREX
Acquired by Nalpropion Pharmaceuticals
Pharmaceutical company focused on development of treatments for obesity.
Early
IPO/Public
San Diego-based clinical stage biopharmaceutical company focused on the development of small molecule inhibitors that can overcome resistance mechanisms in cancer.
Early
Acquired
Acquired by Eli Lilly & Company
Specialized endosurgery devices and instruments for orthopedic and general surgery
Early
Private
Biopharmaceutical company focused on the development and commercialization of novel first in class therapeutic dimer conjugates.
Early
IPO/Acquired
Acquired by: GILEAD
Ouro Medicines is a clinical-stage biopharmaceutical company focused on becoming the leading "immune reset" company, targeting chronic immune-mediated diseases through cell-depleting therapies.
Early
IPO/Acquired
NASDAQ: OYST
Acquired by Viatris
Oyster Point is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
Early
Acquired
Acquired by Ikena
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
Growth
Private
Panacea Medical Technologies is a professional health care company, nurturing a culture of innovation and clinical solutions for diagnosis of cancer. Also premier manufacturer for digital radiography and high end mammography equipment.
Early
IPO/Acquired
NASDAQ: PRTK
Acquired by Novo Holdings and Gurnet Point Capital
Specialty pharmaceutical company focused on addressing therapeutic needs in the fields of psychiatry and sleep medicine
Public/PIPES
Acquired
Acquired by LEO Pharma
Specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products
Early
Acquired
Acquired by LabCorp
Innovative genomic technologies to solve fundamental challenges in oncology
Growth
IPO/Acquired
Acquired by Celgene Corporation
Biotechnology company focused on acquiring, developing and commercializing innovative products in hematology and oncology.
Early
IPO/Public
NASDAQ: PHAS
Focused on discovery and development of therapeutic fusion proteins based on its proprietary Elastin-Like Polypeptide (ELP) technology
Public/PIPES
IPO/Public
NASDAQ: PHAT
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases.
Early
Private
Developing highly accurate, noninvasive diagnostic products for informed cancer management
Early
IPO/Acquired
NASDAQ: RNA
Acquired by BioMarin
Biopharmaceutical company developing therapeutics for orphan genetic diseases with a focus on neuromuscular disorders
Early
IPO/Public
NASDAQ: PTI
Discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network
Early
Acquired
Acquired by Cytyc Corporation
Internal radiation delivery systems for the treatment of solid cancerous tumors
Early
Acquired
Acquired by Emalex
Developing ecopipam, a dopamine D-1 antagonist, for the treatment of Tourette's syndrome, a neurological disorder manifested by motor and phonic tics.
Early
Acquired
Acquired by Shionogi
Qpex Biopharma is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings.
Early
IPO/Acquired
NASDAQ: RARX
Acquired by UCB
Developing a new class of drugs with the diversity and specificity of antibodies, coupled with the oral bioavailability of small molecules
Early
Private
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity.
Early
Private
RedRidge Bio is a biotech company developing transformative therapies for cancer and autoimmune diseases.
Public/PIPES
Acquired
Acquired by Novartis AG
Clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases.
Early
Acquired
Acquired by Boston Scientific
Percutaneous radiofrequency procedure to ablate the basivertebral nerve for the treatment of chronic axial low back pain.
Early
IPO/Acquired
NASDAQ: OKUR
Biopharmaceutical company licensing and developing drugs to treat fibrosis.
Public/PIPES
IPO/Acquired
NASDAQ: RPRX (old)
Acquired by Allergan
Biopharmaceutical company developing therapeutic drugs and formulations designed to treat hormonal and reproductive system disorders.
Early
Acquired
Acquired by Tiger Aesthetics Medical, LLC
Minimally invasive procedure to effectively target the root cause of cellulite.
Early
IPO/Public
NASDAQ: RYTM
Biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases
Public/PIPES
IPO/Public
NASDAQ: RIGL
Clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders
Early
Acquired
Acquired by Smith & Nephew
Medical device start-up company on mission to advance the treatment of rotator cuff disease
Early
Acquired
NASDAQ: SGMT
A clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways.
Public/PIPES
IPO/Public
NASDAQ: SVRA
A clinical stage biopharmaceutical company focused on rare respiratory diseases.
Public/PIPES
IPO/Acquired
NASDAQ: SGEN
Acquired by Pfizer
Biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Early
IPO/Public
NYSE: SENS
Developing broadly enabling chemical sensing technologies based on fluorescence sensing with initial products for implantable glucose sensors and metabolic rate monitors
Early
IPO/Public
NASDAQ: SNTI
Dynamics Special Purpose Corp.
Focused on use of synthetic biology techniques to engineer mammalian cells for a wide variety of applications.
Early
IPO/Public
Sunovion
Bioactive membranes and other separation technologies for the chemical processing and pharmaceutical fields
Early
Private
Implantable neuromodulation device targeting the vagus nerve to treat chronic inflammatory diseases, with an initial indication for rheumatoid arthritis.
Early
Private
A development stage biotechnology company based in Seattle WA and San Diego CA that is establishing itself as a leader in next generation genomic medicine.
Public/PIPES
IPO/Acquired
NASDAQ: SLTM
Acquired by Valeant
Developing transformational aesthetic products, procedures and services.
Early
IPO/Public
William Demant Holding
A new generation of hearing aids based on patented digital signal processing technology
Early
Private
Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn’s disease and ulcerative colitis.
Early
Private
Medical device company focused on degenerative disc disease, vertebral compression fractures, and nucleus replacement
Early
Acquired
Acquired by Olympus Corporation
Medical device company focused on bronchoscopic treatment for emphysema
Early
Private
SpliceBio is a biotechnology company exploiting Protein Splicing to develop next generation gene therapies.
Early
Private
Medical device incubator focused on three novel ophthalmic devices.
Early
Private
Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.
Public/PIPES
IPO/Public
NASDAQ: XERS
Xeris Pharmaceuticals
Global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.
Public/PIPES
NASDAQ: VIRX
Merger between Sunesis and Viracta
Clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics
Public/PIPES
IPO/Acquired
NASDAQ: SPUG
Merged with Astex Therapeutics
Pharmaceutical company dedicated to the discovery and development of novel cancer therapies.
Growth
IPO/Public
IPO/Public
NASDAQ: SUPN
Leveraging expertise in product development and oral drug delivery to develop unique specialty pharmaceutical products
Early
IPO/Acquired
NASDAQ: SURF
Acquired by Coherus
Focused on developing novel oncology-focused antibody therapeutics against series of targets that modulate elements at the boundary of the innate and adaptive immune systems
Early
Acquired
Acquired by Johnson & Johnson
Medical devices for secure, rapid vessel sealing and transection for use in open and laparoscopic surgery
Seed
IPO/Public
NASDAQ: SYBX
Leverages the most advanced technology platform available for the creation of synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease
Early
IPO/Public
NASDAQ: TCON
Clinical stage biopharmaceutical company focused on development of novel therapeutics for cancer and age-related macular degeneration.
Early
Private
Precision therapy company leveraging its ‘click-2-release’ technology platform to unlock full potential of systemic therapies by improving therapeutic window and improving standard of care for patients suffering from severe diseases including cancer.
Early
IPO/Public
NASDAQ: TPST
A clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.
Early
IPO/Acquired
NASDAQ: TSRO
Acquired by GlaxoSmithKline
Oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and commercializing safer and more effective therapeutics
Early
Private
Developing a novel biologic therapy for achondroplasia, the most common form of dwarfism
Early
Acquired
Acquired by Sanofi
Tidal Therapeutics is a preclinical biotech company focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases.
Early
Acquired
Acquired by Abbott Labs
A clinical stage medical device company developing a novel catheter based mapping system used for guiding cardiac ablation procedures for the treatment of arrhythmias like atrial fibrillation
Early
Acquired
Acquired by Medtronic
New class of intervention for the treatment of vascular diseases and other disorders
Early
IPO/Public
NASDAQ: TRVN
Discovering biased GPCR ligands that unlock new biology and avoid side effects as medicines for cardiovascular diseases, pain and inflammation
Growth
IPO/Public
NASDAQ: TRVI
Trevi Therapeutics develops nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia
Public/PIPES
IPO/Acquired
NASDAQ/TSX: TRIL
Acquired by Pfizer
Clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
Early
IPO/Acquired
NASDAQ: TRIV
Acquired by Endologix
Developing endovascular repair devices to treat abdominal aortic aneurysms
Early
Private
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment.
Early
Acquired
Acquired by Merz
=
Developer of a novel ultrasound-based medical device platform for the expanding non-invasive aesthetic treatments market
Early
Acquired
Acquired by McKesson
Comprehensive development, implementation and management solutions for radiation oncology centers
Public/PIPES
Acquired
Merck Sharp & Dohme
A clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases.
Early
IPO/Public
NASDAQ: VRTX
Structural biology and organic chemistry-based human therapies and drugs
Early
Acquired
NYSE: BSX
Acquired by Boston Scientific
Developing minimally invasive and motion preservation technologies for disorders of the spine
Early
Acquired
Acquired by Royal Philips
Vesper Medical is shaping the future of treating deep venous disease through the creation of a next-generation, modular, and uniquely engineered venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins and provides the ability to customize therapy.
Public/PIPES
IPO/Public
NASDAQ: VTGN
A biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders.
Early
IPO/Acquired
NASDAQ: VTAE
Acquired by Allergan
Drug discovery company developing optimized drugs using proprietary computational drug design platform
Early
Private
Sucampo
Biotech company built around a Phase 2/3 ready asset from NIH / NCATS, cyclodextrin, for the treatment of Niemann-Pick C (NPC)
Early
Acquired
Developing a next generation integrated imaging and ablation system for cardiac electrophysiologists
Early
Private
The first all-in-one, mobile, wireless, and hands-free wearable breast pump.
Public/PIPES
IPO/Public
NASDAQ: XFOR
Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers.
Growth
Acquired
Acquired by Valeant Pharmaceuticals
Specialty pharmaceutical company focused on disorders of the central nervous system
Public/PIPES
IPO/Public
NASDAQ: XENE
Clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Early
Private
Xoc Pharmaceuticals is an early-stage, biopharmaceutical company focused on the development of innovative therapeutics. The Company designs novel products “from the ground up” by leveraging information on existing compounds with established pharmacological and clinical history and using its proprietary design and development process to address unmet medical needs, primarily in the CNS disease space. Xoc’s initial product programs are in migraine prevention and Parkinson’s disease maintenance.
Early
Private
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response.
Public/PIPES
IPO/Public
NASDAQ: ZBIO
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients around the world.
Early
Acquired
Acquired by Novartis
Clinical stage biotechnology company progressing novel & differentiated therapies for inflammatory and allergic diseases, using both oral and topical routes of delivery.
Growth
IPO/Acquired
NASDAQ: ZSAN
Acquired by Zosano Pharma Corporation
Painless, convenient transdermal patient administration of therapeutic proteins and vaccines
First invested
Early
Current Status
Private
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: AVEO
Acquired by LG Chem
Commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
First invested
Early
Current Status
Private
Abcuro is a clinical-stage company developing Ulviprubart, a FIC anti-KLRG1 antibody in Ph2/3 pivotal trials for Inclusion Body Myositis (IBM).
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: ACAD
Biopharmaceutical company focused on innovative small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders
First invested
Seed
Current Status
Acquired
Acquired by Johnson & Johnson
Developer of Balloon Sinuplasty
First invested
Early
Current Status
Acquired
Acquired by Nicox S.A.
Specialty pharmaceutical company focused on the development of therapeutics to treat front of the eye diseases
First invested
Seed
Current Status
IPO/Public
NASDAQ: ACRV
Acrivon is developing best-in-class targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon’s unprecedented patient selection method represents a paradigm change in precision oncology drug development.
First invested
Early
Current Status
IPO/Public
NASDAQ: ADAP
Biopharma company developing affinity enhanced T cell receptor (TCR) engineered T cells to treat hematologic and solid tumor cancers.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ/SIX: ADXN
Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders.
First invested
Early
Current Status
Acquired
Acquired by Eli Lilly & Company
China-based, fabless semiconductor company
First invested
Early
Current Status
IPO/Public
German-domiciled and NASDAQ-traded company developing a variety of immuno-oncology therapeutics.
First invested
Early
Current Status
Private
An innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases.
First invested
Seed
Current Status
Private
Ajax is a biotechnology company that focuses on cardiovascular devices
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: AKTX
Biotechnology company developing advanced therapies for autoimmune and inflammatory diseases.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: AKUS
Acquired by Eli Lilly and Company
Akouos is a biotechnology company focused on restoring and preserving hearing.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: ALXA
Staccato
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: ALIM
Biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals
First invested
Growth
Current Status
Acquired
Acquired by Concentra Biosciences
Biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.
First invested
Early
Current Status
Private
Ultra-sustained analgesic products for post-surgical pain management.
First invested
Early
Current Status
Private
Adaptive, closed-loop neuromodulation device targeting the pudendal nerve to treat mixed urinary incontinence.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: FOLD
Oral pharmacological chaperone protein therapies to address diseases that result from protein misfolding
First invested
Early
Current Status
Acquired
Acquired by Pfizer
Developing a novel class of drugs to treat life‐threatening systemic fungal infections.
First invested
Early
Current Status
Acquired
Acquired by Medtronic
Products for the endovascular surgery market
First invested
Early
Current Status
IPO/Public
NASDAQ: ANNX
Annexon Biosciences is leading the development of therapeutic products that halt the progression of complement-mediated neurodegeneration. Annexon’s antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in the loss of nerve connections and inflammation.
First invested
Early
Current Status
Acquired
Acquired by Microvena
Novel device and procedure for preventing cardioembolic stroke in patients with Atrial Fibrillation
First invested
Early
Current Status
IPO/Acquired
NASDAQ: ACLX
Acquired by: GILEAD
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
First invested
Early
Current Status
IPO/Public
NASDAQ: ARDX
Focused on the discovery and development of novel therapeutics acting exclusively in the gastrointestinal tract and devoid of systemic exposure
First invested
Early
Current Status
IPO/Acquired
NASDAQ: ASPM
Acquired by Covidien
Noninvasive anesthesia monitoring systems
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: AUPH
Clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need.
First invested
Growth
Current Status
Private
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation of small-molecule and ADC oncology therapies for patients.
First invested
Early
Current Status
Private
AviadoBio is a biotechnology company developing transformative gene therapies for neurodegenerative disorders using a novel neuroanatomy-led approach to drug delivery.
First invested
Seed
Current Status
Private
Basalt is a tool that integrates into EMRs to help clinical and admissions teams make faster, more consistent decisions by pulling together patient data, applying clinical criteria, and surfacing what actually matters without manual chart digging.
First invested
Early
Current Status
Acquired
Acquired by Life Technologies
Distributor of enzymes and other products allowing manipulation of DNA
First invested
Early
Current Status
IPO/Public
NASDAQ: BDTX
Black Diamond discovers and develops next-wave precision cancer medicines to treat patients with genetically defined cancers driven by oncogenes activated by allosteric mutations.
First invested
Early
Current Status
Private
Brenig is a small molecule drug development company that utilizes an AI/ML approach via a partnership with Expert Systems Inc., a drug accelerator that has spawned multiple best-in-class clinical candidates across multiple therapeutic areas.
First invested
Early
Current Status
Acquired
Acquired by Boston Scientific
Medical device company pioneering solutions to recanalize chronic total occlusions
First invested
Growth
Current Status
IPO/Public
NASDAQ: CRSP
A Basel, Switzerland and Boston, MA-based biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines with the potential to cure serious human genetic diseases
First invested
Public/PIPES
Current Status
IPO/Acquired
NYSE: CTIC
Acquired by Sobi
CTI BioPharma develops drugs that leverage the its expertise in blood-related cancers to address unmet medical needs and find therapies that are less toxic.
First invested
Early
Current Status
Acquired
Acquired by Covidien
Developing a paclitaxel-coated drug-eluting balloon (DEB) for use in treating peripheral vascular disease
First invested
Early
Current Status
IPO/Public
NASDAQ: CVRX
Rheos™ Baroreflex Hypertension Therapy System for treatment of refractory hypertension
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: CADX
Acquired by Mallinckrodt
Hospital-focused biopharmaceutical company
First invested
Early
Current Status
IPO/Acquired
NASDAQ: CTSI
Guidant; Boston Scientific
Instruments and procedures to advance coronary artery bypass graft surgery
First invested
Early
Current Status
Private
Medical device company that is developing a catheter-based neuromodulation solution for the treatment of acute decompensated heart failure (ADHF).
First invested
Early
Current Status
IPO/Acquired
NASDAQ: CVIS
Boston Scientific
Ultrasonic imaging catheter and instrument system for diagnosis of coronary, peripheral and carotid arteries
First invested
Seed
Current Status
Acquired
Acquired by Bristol Myers Squibb
Discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease
First invested
Early
Current Status
Private
Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases.
First invested
Early
Current Status
Acquired
Acquired by Cartiva; Wright Medical Group
Medical device company developing innovative solutions for patients with osteoarthritis and cartilage damage
First invested
Early
Current Status
Acquired
Acquired by Wright Medical
Developer of innovative products for the treatment of cartilage injuries and osteoarthritis
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: CASC
Acquired by Seattle Genetics
Clinical-stage biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer.
First invested
Growth
Current Status
IPO/Public
NASDAQ: CBIO
Biopharmaceutical company focused on drugs to treat CNS disorders by targeting neuronal nicotinic receptors
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: CELC
Minneapolis-based clinical stage biotechnology company focused on the development of molecularly targeted drugs for cancer.
First invested
Early
Current Status
Private
Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development.
First invested
Early
Current Status
IPO/Public
NASDAQ: CERCU
Clinical stage biopharmaceutical company focused on the development of drugs to treat diseases of the central nervous system
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: CSBR
Global preclinical research and clinical specialty testing provider driving excellence in oncology drug development programs.
First invested
Early
Current Status
Acquired
Acquired by Shanghai Pharmaceuticals
Provider of pharmaceuticals, medical supplies and health care information technologies to China's fast-growing healthcare services industry
First invested
Early
Current Status
Private
ChromaCode uses patented mathematical methods and algorithms to enrich signal processing from the most popular life science instrumentation. Their initial products enable high multiplexing of biological tests using existing real-time PCR instruments at a very low cost.
First invested
Early
Current Status
Private
Discovering and developing novel small molecule therapies for difficult-to-treat cancers
First invested
Early
Current Status
IPO/Acquired
NASDAQ: CMTA
Acquired by Ipsen
Biopharmaceutical company focused on developing treatments for rare diseases
First invested
Early
Current Status
IPO/Public
NASDAQ: CLVS
Focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets
First invested
Early
Current Status
Private
A next-generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases.
First invested
Growth
Current Status
Acquired
Acquired by Teva Pharmaceuticals
Focused on development of biotherapeutics for treatment of cancer, heart disease
First invested
Early
Current Status
Private
Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to make every pregnancy around the world safer.
First invested
Early
Current Status
Private
Developing disease-modifying nitro fatty acid platform technology for patients with fibrosis and inflammation-associated orphan diseases.
First invested
Early
Current Status
IPO/Public
NASDAQ: CPTS
Products for the reproductive health market
First invested
Seed
Current Status
Private
CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world.
First invested
Early
Current Status
Acquired
Acquired by Horizon Therapeutics
Treatment of Systemic Sclerosis.
First invested
Early
Current Status
Private
DOTS (Detection On The Spot) is a health tech company creating a revolutionary diagnostics platform with consumer and industrial applications that is changing the field of point of care detection.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: DERM
Acquired by Lilly
A company focused on developing and commercializing innovative new therapies in dermatology
First invested
Early
Current Status
Acquired
Acquired by Schering AG
Therapeutic peptides and imaging agents for thrombus, atherosclerosis and inflammation
First invested
Early
Current Status
IPO/Public
Synthetic peptides for treatment of allergies and asthma
First invested
Growth
Current Status
Acquired
Protein Design Labs
Pharmaceutical company focused on the quality of therapeutics in the acute-care hospital setting
First invested
Seed
Current Status
Private
Biotech company aimed at creating the next generation of genetic medicines.
First invested
Early
Current Status
IPO/Public
St. Jude Medical
Tools for diagnosing and treating cardiac arrhythmias.
First invested
Early
Current Status
Acquired
Acquired by Boston Scientific
NexStent for next-generation carotid artery stenting
First invested
Early
Current Status
Acquired
Acquired by Aerie Pharmaceuticals
Biotechnology startup focused on developing ophthamology products
First invested
Early
Current Status
Acquired
Acquired by Alkermes
Polymer based drug delivery systems for therapeutic proteins
First invested
Early
Current Status
Acquired
Acquired by Ajax Health LLC
EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics, Inc.) is a medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: EPZM
Acquired by Ipsen
Biopharmaceutical company that is creating innovative drugs for major diseases based on important discoveries emerging from the field of Epigenetics
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: ERYP
A clinical-stage biopharma company based in Lyon, France
First invested
Early
Current Status
Acquired
Acquired by Incyte
Escient is a clinical-stage pharmaceutical company focused on discovering and developing first-in-class therapies to address serious, unserved medical needs. The company is led by an experienced team with specific expertise in GPCR drug discovery and development. Escient's pipeline consists of two novel antagonists targeting MRGPRX4 for the treatment of cholestatic pruritis and MRGPRX2 for mast cell mediated disorders.
First invested
Growth
Current Status
Acquired
Acquired by Allergen
Specialty pharmaceutical company focused on urological and women's health products
First invested
Seed
Current Status
Acquired
Acquired by Abbott
Developer of MitraClip for catheter-based edge-to-edge mitral valve repai
First invested
Early
Current Status
Private
Premier medical device incubator focused on developing patient-driven solutions to persistent medical problems.
First invested
Early
Current Status
Private
Implantable remote monitoring device for heart failure patients.
First invested
Early
Current Status
Private
The Foundry is the premier medical device company incubator for inventors to rapidly transform their concepts into companies.
First invested
Early
Current Status
IPO/Acquired
NASDAQ:FOXH
Acquired by Coviden
Medical devices for the treatment of coronary and peripheral arterial disease
First invested
Early
Current Status
Private
Developing a portfolio of clinical-stage small molecule superoxide dismutase mimetics for the treatment of mucositis, cancer and fibrosis
First invested
Early
Current Status
IPO/Public
Genzyme
Non-absorbed, polymer-based pharmaceuticals for the selective gastro-intestinal elimination of substances
First invested
Early
Current Status
IPO/Acquired
Acquired by Sandoz Pharmaceuticals
Products and services based on proprietary technology to implement human gene therapy
First invested
Growth
Current Status
IPO/Public
NASDAQ: GERN
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
First invested
Early
Current Status
IPO/Public
NASDAQ: GLYC
Small molecule therapeutics that mimic the action of carbohydrates to treat inflammatory and infectious diseases
First invested
Public/PIPES
Current Status
IPO/Public
NSDAQ: GOSS
Biopharmaceutical company developing seralutinib for the treatment of pulmonary arterial hypertension (PAH).
First invested
Early
Current Status
IPO/Public
Johnson & Johnson
Endometrial ablation system for the treatment of excessive uterine bleeding
First invested
Public/PIPES
Current Status
Acquired
Acquired by Inverness Medical
INRatio anti-coagulation monitor for patient self-testing
First invested
Early
Current Status
Acquired
Acquired by Eli Lilly and Company
Private biopharmaceuticals company pioneering the discovery of novel drugs using its expertise in Transient Receptor Protocols in ion channels and molecular regeneration
First invested
Early
Current Status
IPO/Acquired
NASDAQ: HPTX
Acquired by Horizon Pharma
Specialty therapeutics company focused on gastrointestinal and hepatology diseases and programs
First invested
Early
Current Status
IPO/Public
NASDAQ: IMRA
Developing IMR-687, an IND-ready PDE9 (phosphodiesterase 9) inhibitor for sickle cell disease
First invested
Public/PIPES
Current Status
IPO/Public
Amgen
Lymphokines for therapeutic use as anti-cancer agents supporting the human immune system
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: IMMU
Acquired by Gilead Sciences (NASDAQ: GILD)
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: INFI
Clinical-stage biotechnology company developing a therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer.
First invested
Public/PIPES
Current Status
IPO/Acquired
Acquired by Bristol Myers Squibb
Biopharmaceutical company focused on novel antibody-based products for serious hospital-associated bacterial and fungal infections
First invested
Early
Current Status
Acquired
Acquired by BioMarin Pharmaceutical
Biotechnology company developing new medicines to treat rare disorders of calcification with initial focus on enzyme replacement therapy for devastating and debilitating rare diseases that largely impact infants, children and young adults.
First invested
Early
Current Status
IPO/Acquired
NYSE:PHG
Acquired by Royal Philips
A medical device company that is developing a novel, minimally invasive medical device for the treatment of peripheral arterial disease (PAD).
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: ITMN
Acquired by Roche Holding AG
Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.
First invested
Early
Current Status
Private
Developing device-based therapies for soft-tissue injuries of the spine
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: IVA
Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
First invested
Early
Current Status
Acquired
Acquired by Novo Nordisk
Inversago Pharma specializes in the development of new therapies focusing on CB1blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
First invested
Early
Current Status
IPO/Acquired
Acquired by Intercell AG
Vaccines and immune system stimulants delivered through novel needle-free transcutaneous immunization
First invested
Early
Current Status
IPO/Public
Cutera
Ophthalmic probes and diode laser-based systems
First invested
Early
Current Status
Acquired
Acquired by Alcon
Developing products for the treatment of eye diseases
First invested
Early
Current Status
IPO/Acquired
NASAQ: KRRO
Merged with Frequency Therapeutics
A preclinical-stage biopharma company that is developing novel RNA editing therapeutics to treat genetically-driven disease. Korro’s OPERA platform coopts the body’s ADAR system to make targeted edits to a single RNA base.
First invested
Early
Current Status
Private
Collaborates with client hospitals and community physicians in the development and management of a proven disease management program for the care of gastroesophageal reflux disease (GERD)
First invested
Public/PIPES
Current Status
Private
LeonaBio is dedicated to the development of novel therapeutics for diseases with high unmet needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patient’s lives.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: LXRX
Biopharmaceutical company that has harnessed the power of genetics for drug discovery.
First invested
Early
Current Status
IPO/Public
Invitrogen
Tissue culture media, immunodiagnostics and test kits for the life sciences research field
First invested
Early
Current Status
IPO/Public
NASDAQ: LQDA
Utilizes a proprietary nanotechnology platform to develop precisely engineered products in the materials and life sciences sectors
First invested
Early
Current Status
IPO/Acquired
NASDAQ: LOXO
Acquired by Eli Lilly & Co.
Biopharma company developing targeted cancer therapies for genetically-defined patient populations
First invested
Early
Current Status
Acquired
Acquired by Shire
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health.
First invested
Early
Current Status
Acquired
Acquired by NewLink Genetics
Developing a novel therapeutic for the rare disease Creatine Transporter Deficiency, an inborn error of metabolism
First invested
Growth
Current Status
Private
Lungpacer Medical Inc. is developing a novel therapeutic solution for preserving or restoring the integrity and strength of the diaphragm muscle in critically ill patients who require mechanical ventilation.
First invested
Early
Current Status
IPO/Public
NASDAQ: MBX
Advancing potential breakthrough medicines for rare endocrine diseases of substantial medical need with validated molecular targets.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: MEIP
Oncology company focused on the clinical development of novel therapies for cancer
First invested
Early
Current Status
Private
Next-generation percutaneous left ventricular assist device targeting high-risk percutaneous coronary intervention and cardiogenic shock.
First invested
Early
Current Status
IPO/Public
NASDAQ: MRKR
Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood and solid tumor cancers.
First invested
Early
Current Status
IPO/Public
NASDAQ: MRSN
Biopharmaceutical company that is creating the next generation of antibody drug conjugates using its Fleximer-ADC technology
First invested
Early
Current Status
IPO/Public
Metacrine is a biotech company developing innovative therapeutics for liver, gastrointestinal, and metabolic diseases. The lead program is a best-in-class FXR agonist for multiple diseases, including non-alcoholic steatohepatitis (NASH).
First invested
Early
Current Status
IPO/Public
NASDAQ: UTRS
Medical device start-up company focused on women's health care
First invested
Early
Current Status
IPO/Public
NASDAQ: MIRN
Biopharmaceutical company focused on microRNA (miRNA)-directed oncology therapies
First invested
Early
Current Status
IPO/Public
NASDAQ: MIRM
Mirum Pharmaceuticals, Inc. is a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.
First invested
Growth
Current Status
IPO/Public
NASDAQ: GLUE
Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins by creating a platform that designs small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable.
First invested
Early
Current Status
Acquired
Acquired by Allergan
Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases.
First invested
Early
Current Status
Private
Implantable shock absorber (ISA) that unloads the knee, relieves pain, and improves function for patients with osteoarthritis.
First invested
Early
Current Status
IPO/Public
IPO/Public Gilead Sciences
Biopharmaceutical company focused on small molecule therapeutics for the treatment of cardiovascular disorders.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: NKTR
Research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet needs.
First invested
Public/PIPES
Current Status
IPO/Public
Covidien
Patient monitoring instruments and disposable supplies for use in surgery
First invested
Early
Current Status
Acquired
Teleflex
Developer of the UroLift
First invested
Early
Current Status
Private
Developing a personal use device to treat migraine using transcranial magnetic stimulation
First invested
Early
Current Status
IPO/Public
NASDAQ: NPCE
Developing implantable devices for the treatment of neurological disorders by responsive brain stimulation
First invested
Early
Current Status
IPO/Acquired
NYSE: NVRO
Next generation high frequency spinal cord stimulation for the treatment of chronic pain
First invested
Growth
Current Status
Private
Leading Chinese producer of active pharmaceutical ingredients (API) for global markets
First invested
Early
Current Status
Private
Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: NITE
Acquired by Biogen
Private biopharmaceutical company focused on the development of therapies for retinal dystrophies.
First invested
Early
Current Status
IPO/Public
NASDAQ: NKTX
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer.
First invested
Growth
Current Status
Acquired
Cytyc Corporation
Cytyc
Innovative medical devices to improve the quality and cost-effectiveness of healthcare for women
First invested
Early
Current Status
Private
China's leading speciality pharmaceutical developer
First invested
Early
Current Status
Acquired
Aytu BioScience, Inc.
Nuelle™ is a sexual wellness company focused on delivering groundbreaking solutions made specifically for women, backed by science that promote individual vitality and healthy relationships.
First invested
Early
Current Status
IPO/Public
NASDAQ: OBSV
ObsEva is a clinical stage biopharmaceutical company focusing on the development of a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth.
First invested
Early
Current Status
Acquired
Acquired by Allergan
Developing a novel treatment for Dry Eye, a disease affecting millions of people worldwide
First invested
Early
Current Status
IPO/Acquired
NASDAQ: OMTH
Acquired by Astrazeneca
Emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia
First invested
Early
Current Status
Private
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery.
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: OREX
Acquired by Nalpropion Pharmaceuticals
Pharmaceutical company focused on development of treatments for obesity.
First invested
Early
Current Status
IPO/Public
San Diego-based clinical stage biopharmaceutical company focused on the development of small molecule inhibitors that can overcome resistance mechanisms in cancer.
First invested
Early
Current Status
Acquired
Acquired by Eli Lilly & Company
Specialized endosurgery devices and instruments for orthopedic and general surgery
First invested
Early
Current Status
Private
Biopharmaceutical company focused on the development and commercialization of novel first in class therapeutic dimer conjugates.
First invested
Early
Current Status
IPO/Acquired
Acquired by: GILEAD
Ouro Medicines is a clinical-stage biopharmaceutical company focused on becoming the leading "immune reset" company, targeting chronic immune-mediated diseases through cell-depleting therapies.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: OYST
Acquired by Viatris
Oyster Point is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
First invested
Early
Current Status
Acquired
Acquired by Ikena
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
First invested
Growth
Current Status
Private
Panacea Medical Technologies is a professional health care company, nurturing a culture of innovation and clinical solutions for diagnosis of cancer. Also premier manufacturer for digital radiography and high end mammography equipment.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: PRTK
Acquired by Novo Holdings and Gurnet Point Capital
Specialty pharmaceutical company focused on addressing therapeutic needs in the fields of psychiatry and sleep medicine
First invested
Public/PIPES
Current Status
Acquired
Acquired by LEO Pharma
Specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products
First invested
Early
Current Status
Acquired
Acquired by LabCorp
Innovative genomic technologies to solve fundamental challenges in oncology
First invested
Growth
Current Status
IPO/Acquired
Acquired by Celgene Corporation
Biotechnology company focused on acquiring, developing and commercializing innovative products in hematology and oncology.
First invested
Early
Current Status
IPO/Public
NASDAQ: PHAS
Focused on discovery and development of therapeutic fusion proteins based on its proprietary Elastin-Like Polypeptide (ELP) technology
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: PHAT
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases.
First invested
Early
Current Status
Private
Developing highly accurate, noninvasive diagnostic products for informed cancer management
First invested
Early
Current Status
IPO/Acquired
NASDAQ: RNA
Acquired by BioMarin
Biopharmaceutical company developing therapeutics for orphan genetic diseases with a focus on neuromuscular disorders
First invested
Early
Current Status
IPO/Public
NASDAQ: PTI
Discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network
First invested
Early
Current Status
Acquired
Acquired by Cytyc Corporation
Internal radiation delivery systems for the treatment of solid cancerous tumors
First invested
Early
Current Status
Acquired
Acquired by Emalex
Developing ecopipam, a dopamine D-1 antagonist, for the treatment of Tourette's syndrome, a neurological disorder manifested by motor and phonic tics.
First invested
Early
Current Status
Acquired
Acquired by Shionogi
Qpex Biopharma is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: RARX
Acquired by UCB
Developing a new class of drugs with the diversity and specificity of antibodies, coupled with the oral bioavailability of small molecules
First invested
Early
Current Status
Private
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity.
First invested
Early
Current Status
Private
RedRidge Bio is a biotech company developing transformative therapies for cancer and autoimmune diseases.
First invested
Public/PIPES
Current Status
Acquired
Acquired by Novartis AG
Clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases.
First invested
Early
Current Status
Acquired
Acquired by Boston Scientific
Percutaneous radiofrequency procedure to ablate the basivertebral nerve for the treatment of chronic axial low back pain.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: OKUR
Biopharmaceutical company licensing and developing drugs to treat fibrosis.
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: RPRX (old)
Acquired by Allergan
Biopharmaceutical company developing therapeutic drugs and formulations designed to treat hormonal and reproductive system disorders.
First invested
Early
Current Status
Acquired
Acquired by Tiger Aesthetics Medical, LLC
Minimally invasive procedure to effectively target the root cause of cellulite.
First invested
Early
Current Status
IPO/Public
NASDAQ: RYTM
Biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: RIGL
Clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders
First invested
Early
Current Status
Acquired
Acquired by Smith & Nephew
Medical device start-up company on mission to advance the treatment of rotator cuff disease
First invested
Early
Current Status
Acquired
NASDAQ: SGMT
A clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: SVRA
A clinical stage biopharmaceutical company focused on rare respiratory diseases.
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: SGEN
Acquired by Pfizer
Biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
First invested
Early
Current Status
IPO/Public
NYSE: SENS
Developing broadly enabling chemical sensing technologies based on fluorescence sensing with initial products for implantable glucose sensors and metabolic rate monitors
First invested
Early
Current Status
IPO/Public
NASDAQ: SNTI
Dynamics Special Purpose Corp.
Focused on use of synthetic biology techniques to engineer mammalian cells for a wide variety of applications.
First invested
Early
Current Status
IPO/Public
Sunovion
Bioactive membranes and other separation technologies for the chemical processing and pharmaceutical fields
First invested
Early
Current Status
Private
Implantable neuromodulation device targeting the vagus nerve to treat chronic inflammatory diseases, with an initial indication for rheumatoid arthritis.
First invested
Early
Current Status
Private
A development stage biotechnology company based in Seattle WA and San Diego CA that is establishing itself as a leader in next generation genomic medicine.
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: SLTM
Acquired by Valeant
Developing transformational aesthetic products, procedures and services.
First invested
Early
Current Status
IPO/Public
William Demant Holding
A new generation of hearing aids based on patented digital signal processing technology
First invested
Early
Current Status
Private
Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn’s disease and ulcerative colitis.
First invested
Early
Current Status
Private
Medical device company focused on degenerative disc disease, vertebral compression fractures, and nucleus replacement
First invested
Early
Current Status
Acquired
Acquired by Olympus Corporation
Medical device company focused on bronchoscopic treatment for emphysema
First invested
Early
Current Status
Private
SpliceBio is a biotechnology company exploiting Protein Splicing to develop next generation gene therapies.
First invested
Early
Current Status
Private
Medical device incubator focused on three novel ophthalmic devices.
First invested
Early
Current Status
Private
Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: XERS
Xeris Pharmaceuticals
Global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs.
First invested
Public/PIPES
Current Status
NASDAQ: VIRX
Merger between Sunesis and Viracta
Clinical-stage biopharmaceutical company focused on the development and commercialization of new oncology therapeutics
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ: SPUG
Merged with Astex Therapeutics
Pharmaceutical company dedicated to the discovery and development of novel cancer therapies.
First invested
Growth
Current Status
IPO/Public
IPO/Public
NASDAQ: SUPN
Leveraging expertise in product development and oral drug delivery to develop unique specialty pharmaceutical products
First invested
Early
Current Status
IPO/Acquired
NASDAQ: SURF
Acquired by Coherus
Focused on developing novel oncology-focused antibody therapeutics against series of targets that modulate elements at the boundary of the innate and adaptive immune systems
First invested
Early
Current Status
Acquired
Acquired by Johnson & Johnson
Medical devices for secure, rapid vessel sealing and transection for use in open and laparoscopic surgery
First invested
Seed
Current Status
IPO/Public
NASDAQ: SYBX
Leverages the most advanced technology platform available for the creation of synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease
First invested
Early
Current Status
IPO/Public
NASDAQ: TCON
Clinical stage biopharmaceutical company focused on development of novel therapeutics for cancer and age-related macular degeneration.
First invested
Early
Current Status
Private
Precision therapy company leveraging its ‘click-2-release’ technology platform to unlock full potential of systemic therapies by improving therapeutic window and improving standard of care for patients suffering from severe diseases including cancer.
First invested
Early
Current Status
IPO/Public
NASDAQ: TPST
A clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: TSRO
Acquired by GlaxoSmithKline
Oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and commercializing safer and more effective therapeutics
First invested
Early
Current Status
Private
Developing a novel biologic therapy for achondroplasia, the most common form of dwarfism
First invested
Early
Current Status
Acquired
Acquired by Sanofi
Tidal Therapeutics is a preclinical biotech company focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases.
First invested
Early
Current Status
Acquired
Acquired by Abbott Labs
A clinical stage medical device company developing a novel catheter based mapping system used for guiding cardiac ablation procedures for the treatment of arrhythmias like atrial fibrillation
First invested
Early
Current Status
Acquired
Acquired by Medtronic
New class of intervention for the treatment of vascular diseases and other disorders
First invested
Early
Current Status
IPO/Public
NASDAQ: TRVN
Discovering biased GPCR ligands that unlock new biology and avoid side effects as medicines for cardiovascular diseases, pain and inflammation
First invested
Growth
Current Status
IPO/Public
NASDAQ: TRVI
Trevi Therapeutics develops nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia
First invested
Public/PIPES
Current Status
IPO/Acquired
NASDAQ/TSX: TRIL
Acquired by Pfizer
Clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: TRIV
Acquired by Endologix
Developing endovascular repair devices to treat abdominal aortic aneurysms
First invested
Early
Current Status
Private
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment.
First invested
Early
Current Status
Acquired
Acquired by Merz
=
Developer of a novel ultrasound-based medical device platform for the expanding non-invasive aesthetic treatments market
First invested
Early
Current Status
Acquired
Acquired by McKesson
Comprehensive development, implementation and management solutions for radiation oncology centers
First invested
Public/PIPES
Current Status
Acquired
Merck Sharp & Dohme
A clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases.
First invested
Early
Current Status
IPO/Public
NASDAQ: VRTX
Structural biology and organic chemistry-based human therapies and drugs
First invested
Early
Current Status
Acquired
NYSE: BSX
Acquired by Boston Scientific
Developing minimally invasive and motion preservation technologies for disorders of the spine
First invested
Early
Current Status
Acquired
Acquired by Royal Philips
Vesper Medical is shaping the future of treating deep venous disease through the creation of a next-generation, modular, and uniquely engineered venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins and provides the ability to customize therapy.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: VTGN
A biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders.
First invested
Early
Current Status
IPO/Acquired
NASDAQ: VTAE
Acquired by Allergan
Drug discovery company developing optimized drugs using proprietary computational drug design platform
First invested
Early
Current Status
Private
Sucampo
Biotech company built around a Phase 2/3 ready asset from NIH / NCATS, cyclodextrin, for the treatment of Niemann-Pick C (NPC)
First invested
Early
Current Status
Acquired
Developing a next generation integrated imaging and ablation system for cardiac electrophysiologists
First invested
Early
Current Status
Private
The first all-in-one, mobile, wireless, and hands-free wearable breast pump.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: XFOR
Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers.
First invested
Growth
Current Status
Acquired
Acquired by Valeant Pharmaceuticals
Specialty pharmaceutical company focused on disorders of the central nervous system
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: XENE
Clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
First invested
Early
Current Status
Private
Xoc Pharmaceuticals is an early-stage, biopharmaceutical company focused on the development of innovative therapeutics. The Company designs novel products “from the ground up” by leveraging information on existing compounds with established pharmacological and clinical history and using its proprietary design and development process to address unmet medical needs, primarily in the CNS disease space. Xoc’s initial product programs are in migraine prevention and Parkinson’s disease maintenance.
First invested
Early
Current Status
Private
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response.
First invested
Public/PIPES
Current Status
IPO/Public
NASDAQ: ZBIO
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients around the world.
First invested
Early
Current Status
Acquired
Acquired by Novartis
Clinical stage biotechnology company progressing novel & differentiated therapies for inflammatory and allergic diseases, using both oral and topical routes of delivery.
First invested
Growth
Current Status
IPO/Acquired
NASDAQ: ZSAN
Acquired by Zosano Pharma Corporation
Painless, convenient transdermal patient administration of therapeutic proteins and vaccines

Deep perspectives,deep insight.

Stage
Status
Theme
Join the conversation.